pharma · Head and Neck Neoplasms · Rheumatoid Arthritis
Chinese University of
Chinese University of Hong Kong
Chinese University of is a pharma organization headquartered in CN. Primary therapeutic focus areas include Head and Neck Neoplasms, Rheumatoid Arthritis, Rare Tumor, Essential Hypertension, Primary Esophageal Motility D
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 42
- Drugs
- 55
- Patents
- 0
Iparomlimab/Tuvonralimab
Phase 2 · small molecule · LOCALLY ADVANCED CERVICAL CANCERS
Iparomlimab/Tuvonralimab for LOCALLY ADVANCED CERVICAL CANCERS is a Phase 2 program (small_molecule) at Chinese University of Hong Kong with 1 ClinicalTrials.gov record(s).
Internal code QLMA-IIT-CC-001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Chinese University of Hong Kong
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- LOCALLY ADVANCED CERVICAL CANCERS
- Status
- active
- Trials
- 1